Late radiation side effects after postoperative IMRT and brachytherapy for cervical and endometrial cancer
Assessment of Late Gastrointestinal and Genitourinary Toxicities in Cervical and Endometrial Cancer Requiring Postoperative IMRT and/or Brachytherapy
This project will see how often and how severe late gastrointestinal and urinary side effects are in people with cervical or endometrial cancer who received postoperative IMRT and/or brachytherapy at Tata Memorial Hospital.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | Female |
| Sponsor | Tata Memorial Hospital Government |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Mumbai, Maharashtra) |
| Trial ID | NCT07435623 on ClinicalTrials.gov |
What this trial studies
This observational review will collect treatment and follow-up information for adults with confirmed cervical or endometrial cancer who received adjuvant IMRT and/or brachytherapy at Tata Memorial Center (TMH/ACTREC). Patients with incomplete treatment details, residual disease after surgery, postoperative recurrences, immunosuppressive disorders, or missing follow-up will be excluded. Investigators will analyze clinical records, toxicity grading, imaging, and follow-up visits to characterize late gastrointestinal and genitourinary toxicities after postoperative radiotherapy. The analysis aims to describe timing, severity, and potential risk factors for late toxicities in this single-center Indian cohort.
Who should consider this trial
Good fit: Ideal candidates are adults (>18) with confirmed cervical or endometrial cancer who completed adjuvant IMRT and/or brachytherapy at Tata Memorial Center and have available follow-up records.
Not a fit: Patients treated elsewhere, those with incomplete treatment details, residual disease, postoperative recurrences, immunosuppression, or who are lost to follow-up are unlikely to be included or to benefit from the findings.
Why it matters
Potential benefit: If successful, the findings could help clinicians better counsel patients, tailor follow-up, and modify treatment planning to reduce late bowel and bladder side effects.
How similar studies have performed: Previous work has shown that IMRT can reduce some pelvic radiation toxicities compared with older techniques, but detailed data on late side effects after postoperative IMRT combined with brachytherapy—especially from Indian cohorts—are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients more than 18 years of age at the time of diagnosis. * All patients with confirmed histological diagnosis of cervical or endometrial cancer. * Only those patients who have received adjuvant (chemo)radiotherapy with IMRT and/or brachytherapy at TMH/ACTREC will be included. * Patients whose follow up information available Exclusion Criteria: * Patients with incomplete treatment details. * Patient having residual disease post-surgery. * Patient treated for post-operative recurrences. * Patient who lost to follow up. * Patients with Immunosuppressive disorder
Where this trial is running
Mumbai, Maharashtra
- Tata Memorial Center — Mumbai, Maharashtra, India (Recruiting)
Study contacts
- Study coordinator: Supriya Chopra
- Email: supriyasastri@gmail.com
- Phone: 02227405000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.